

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
and Trademark Office; U.S. DEPARTMENT OF COMMERCE
displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/735,712
		Filing Date	December 12, 2000
		First Named Inventor	Walke
		Group Art Unit	1645
		Examiner Name	To Be Assigned
Sheet 1 of 3	1 C184	Attorney Docket Number	LEX-0109-USA

JUL 1 0 2001 **JUL 1 9 2001** **PATENT & TRADEMARK OFFICE** **U.S. Patent Document** **Kind Code⁴** **1 C184** **U.S. Patent Office**

Examiner Initials*	Cite No. ¹	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
					Kind Code ⁵ (if known)	T ⁶
R.Li	AA	4,215,051	Schroeder et al	07/29/80		
R.Li	AB	4,376,110	David et al	03/08/83		
R.Li	AC	4,594,595	Struckman	06/10/86		
	AD	4,631,211	Houghten	12/23/86		
	AE	4,683,202	Mullis	07/28/87		
	AF	4,689,405	Frank et al	08/25/87		
	AG	4,713,326	Dattagupta et al	12/15/87		
	AH	4,946,778	Ladner et al	08/07/90		
	AI	5,252,743	Barrett et al	10/12/93		
	AJ	5,424,186	Fodor et al	06/13/95		
	AK	5,445,934	Fodor et al	08/29/95		
	AL	5,459,127	Felgner et al	10/17/95		
	AM	5,556,752	Lockhart et al	09/17/96		
	AN	5,700,637	Southern	12/23/97		
	AO	5,744,305	Fodor et al	04/28/98		
	AP	5,837,458	Minshull et al	11/17/98		
	AQ	5,877,397	Lonberg et al	03/02/99		
	AR	5,948,767	Scheule et al.	09/07/99		
	AS	5,977,072	Bandman et al	11/02/99		
↓	AT	6,075,181	Kucherlapati et al	06/13/00		
R.Li	AU	6,110,490	Thierry	08/29/00		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		

Examiner Signature	Ruixiang Li	Date Considered	11/30/01
--------------------	-------------	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
TECH CENTER 1600
JUL 2 2001
1600 P 290

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT JUL 19 2001 (use as many sheets as necessary)		Complete if Known	
		Application Number	09/735,712
		Filing Date	December 12, 2000
		First Named Inventor	Walke
		Group Art Unit	1645
		Examiner Name	To Be Assigned
		Attorney Docket Number	LEX-0109-USA
		RECEIVED	
		JUL 23 2001	
		TECH CENTER 1600/2900	
Patent & Trademark Office Sheet 2 of 2	of	3	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R.L.	AV	Benton et al, 1977, "Screening Agt Recombinant Clones by Hybridization to Single Plaques in situ", Science 196:180-182	
	AW	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	
	AX	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	
	AY	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	
	AZ	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetraethylimidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.	
	BA	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	
	BB	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.	
	BC	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.	
	BD	Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.	
	BE	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.	
	BF	Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.	
	BG	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.	
	BH	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
	BI	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	
	BJ	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	
	BK	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.	
	BL	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
	BM	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	
	BN	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
	BO	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
	BP	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
	BQ	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
	BR	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
	BS	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	
	BT	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT JUL 19 2001 PATENT & TRADEMARK OFFICE			Complete if Known	
			Application Number	09/735,712
			Filing Date	December 12, 2000
			First Name Inventor	Walke
			Group Art Unit	1645
			Examiner Name	To Be Assigned
Sh	(use as many sheets as necessary)	of	3	Attorney Docket Number
LEX-0109-USA				

RECEIVED
JUL 23 2001
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
R-Li	BU	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.		
	BV	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.		
	BW	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.		
↓	BX	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.		

Examiner Signature	<i>Ruthany L</i>	Date Considered	11/30/01
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.